Assessment Tools to Measure Impact of Dermatologic and Mucosal Adverse Eventsa

Get Permission

aEditor’s Note: References to these tools are provided for educational purposes only. Terms of use for these tools may vary and some may be subject to copyright restrictions.

Patient-Reported Outcomes version of the CTCAE (PRO-CTCAE)

Patient Completed mcAEs Specific Symptom Experience Diary for Targeted Therapies


Skindex-16 and Hair Specific Skindex-29


mIAS Scale

Related Articles

How to Measure the Impact of Dermatologic and Mucosal Adverse Events on Symptom Burden and Quality of Life

Targeted anticancer therapies like epidermal growth factor receptor (EGFR) inhibitors, multitargeted tyrosine kinase inhibitors (mTKIs), and mammalian target of rapamycin (mTOR) inhibitors frequently result in dermatologic adverse events and mucosal adverse events, or, taken together, mucocutaneous ...




By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.